Lindsey Ingerman James

Lindsey Ingerman James

Auto-generated profile, based on publicly available information

Lindsey Ingerman James

University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cell Chemical Biology
Verified
Journal Article
Closed access
FPFrances Potjewyd
Frances Potjewyd
ATAnne-Marie W. Turner
Anne-Marie W. Turner
JBJoshua Beri
Joshua Beri
JRJustin Rectenwald
Justin Rectenwald
JNJacqueline L. Norris-Drouin
Jacqueline L. Norris-Drouin
LJLindsey I. James
Lindsey I. James

1 March 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
LHLianxin Hu
Lianxin Hu
HXHaibiao Xie
Haibiao Xie
XLXijuan Liu
Xijuan Liu
FPFrances Potjewyd
Frances Potjewyd
LJLindsey I. James
Lindsey I. James
QZQING ZHANG
QING ZHANG
TANK binding kinase 1 (TBK1) is an important kinase involved in the innate immune response. Here we discover that TBK1 is hyperactivated by von Hippel-Lindau (VHL) loss or hypoxia in cancer cells. Tumors from patients with kidney cancer with VHL loss display elevated TBK1 phosphorylation. Loss of TBK1 via genetic ablation, pharmacologic inhibition, or a new cereblon-based proteolysis targeting chimera specifically inhibits VHL-deficient kidney cancer cell growth, while leaving VHL wild-type cells intact. TBK1 depletion also significantly blunts kidney tumorigenesis in an orthotopic xenograft model in vivo. Mechanistically, TBK1 hydroxylation on Proline 48 triggers VHL as well as the phosphatase PPM1B binding that leads to decreased TBK1 phosphorylation. We identify that TBK1 phosphorylates p62/SQSTM1 on Ser366, which is essential for p62 stability and kidney cancer cell proliferation. Our results establish that TBK1, distinct from its role in innate immune signaling, is a synthetic lethal target in cancer with VHL loss. Significance: The mechanisms that lead to TBK1 activation in cancer and whether this activation is connected to its role in innate immunity remain unclear. Here, we discover that TBK1, distinct from its role in innate immunity, is activated by VHL loss or hypoxia in cancer. See related commentary by Bakouny and Barbie, p. 348. This article is highlighted in the In This Issue feature, p. 327

15 November 2021 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
DDDavid Dilworth
David Dilworth
RHRonan P. Hanley
Ronan P. Hanley
RFRenato Ferreira de Freitas
Renato Ferreira de Freitas
AAAbdellah Allali-Hassani
Abdellah Allali-Hassani
MZMengqi Zhou
Mengqi Zhou
MSMatthieu Schapira
Matthieu Schapira

17 December 2019 in ACS Chemical Biology
Verified
Journal Article
Closed access
CFCaroline A. Foley
Caroline A. Foley
FPFrances Potjewyd
Frances Potjewyd
KLKelsey N. Lamb
Kelsey N. Lamb
LJLindsey I. James
Lindsey I. James
SFStephen V. Frye
Stephen V. Frye

5 April 2013 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
LJLindsey I. James
Lindsey I. James
JBJoshua E. Beaver
Joshua E. Beaver
NRNatalie W. Rice
Natalie W. Rice
MWMarcey L. Waters
Marcey L. Waters

12 July 2018 in ACS Central Science
Verified
Journal Article
Open access
SPSamuel J. Pellock
Samuel J. Pellock
BCBenjamin C. Creekmore
Benjamin C. Creekmore
WWWilliam G. Walton
William G. Walton
NMNaimee Mehta
Naimee Mehta
KBKristen A. Biernat
Kristen A. Biernat
MRMatthew Redinbo
Matthew Redinbo
Microbial β-glucuronidases (GUSs) cause severe gut toxicities that limit the efficacy of cancer drugs and other therapeutics. Selective inhibitors of bacterial GUS have been shown to alleviate these side effects. Using structural and chemical biology, mass spectrometry, and cell-based assays, we establish that piperazine-containing GUS inhibitors intercept the glycosyl-enzyme catalytic intermediate of these retaining glycosyl hydrolases. We demonstrate that piperazine-based compounds are substrate-dependent GUS inhibitors that bind to the GUS–GlcA catalytic intermediate as a piperazine-linked glucuronide (GlcA, glucuronic acid). We confirm the GUS-dependent formation of inhibitor–glucuronide conjugates by LC–MS and show that methylated piperazine analogs display significantly reduced potencies. We further demonstrate that a range of approved piperazine- and piperidine-containing drugs from many classes, including those for the treatment of depression, infection, and cancer, function by the same mechanism, and we confirm through gene editing that these compounds selectively inhibit GUS in living bacterial cells. Together, these data reveal a unique mechanism of GUS inhibition and show that a range of therapeutics may impact GUS activities in the human gut.